Global Hypercalcemia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4564284
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Amgen, Inc.
  • Bayer Pharma AG
  • Cipla, Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • MORE
Hypercalcemia Treatment Market- Growth, Future Prospects and Competitive Analysis, 2018-2026, the global hypercalcemia treatment market was valued at US$ 9,544.1 Mn in 2017 and expected to reach US$ 23,707.8 Mn by 2026, expanding at a CAGR of 10.7% from 2018 to 2026.

Market Insights
The global hypercalcemia treatment market is projected to reach US$ 23,707.8 Mn by 2026 from US$ 9,544.1 Mn in 2017, growing at a CAGR of 10.7% during the forecast period from 2018 to 2026. Hypercalcemia is a metabolic disorder caused by elevated levels of calcium, with serum calcium levels above 2.6 mmol/L. Hypercalcemia is generally a result of overactive parathyroid glands and may occur in cancer patients, majorly in lung and breast cancer patients. Some other factors contributing development of disorder includes hereditary factors, severe dehydration, medications, and supplements. Patients are prescribed calcium regulating therapeutics.

Based on the drug class, the global hypercalcemia treatment market is segmented into bisphosphonates, calcitonin, glucocorticoids, calcimimetic agents, and denusomab. Bisphosphonates is further sub-segmented into clodronate, etidronate, ibandronate, pamidronate, and zoledronic acid. In 2017, bisphosphonates segment dominated the global hypercalcemia treatment market due to increased preference for treatment of the disease. Other drug classes including glucocorticoids and calcimimetic agents are expected to experience a steady growth during the forecast period. As generics dominates the market, label extension of the drugs for the treatment of more indications further expected to contribute to the growth of the market.

Based on geographical demarcation, North America and Europe collectively contributed over 63% of the global hypercalcemia treatment market share in 2017 with North America in lead. High prevalence of the malignancy-related hypercalcemia and increased awareness of the disease in both the regions are the prime factors for the dominance. Asia Pacific and Latin America hypercalcemia treatment market are projected to witness the fastest growth at a double digit CAGR during the forecast period due to growing healthcare expenditure and increasing awareness related to hypercalcemia.

The global hypercalcemia treatment market is highly fragmented due to the presence of numerous local and international market players. Since most of the therapeutics are generic, several players are manufacturing the drugs and competing in the global market. Further, some of the players are investing in research & development for hypercalcemia to capture the prominent market share. Key players in the market include Amgen, Inc., Bayer Pharma AG, Mylan N.V., Pfizer Inc., Cipla, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, and Dr. Reddy’s Laboratories Ltd.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen, Inc.
  • Bayer Pharma AG
  • Cipla, Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Market Segmentation
1.3 Research Scope
1.4 Research Methodology
1.4.1 Phase I – Secondary Research
1.4.2 Phase II – Primary Research
1.4.3 Phase III – Expert Panel Review
1.4.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Hypercalcemia Treatment Market Portraiture
2.2 Global Hypercalcemia Treatment Market, by Drug Class, 2017 (US$ Mn)
2.3 Global Hypercalcemia Treatment Market, by Geography, 2017 (US$ Mn)

Chapter 3 Global Hypercalcemia Treatment Market: Dynamics & Future Outlook
3.1 Market Overview
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Adoption of Combination Therapy in Treatment of Hypercalcemia
3.2.1.2 Rising Prevalence of Malignancy and Hyperparathyroidism-related Hypercalcemia
3.2.2 Challenges
3.2.2.1 Challenge 1
3.2.3 Opportunities
3.2.3.1 Opportunity 1
3.3 Attractive Investment Proposition, by Geography, 2017
3.4 Competitive Landscape, by Key Players, 2017

Chapter 4 Global Hypercalcemia Treatment Market, by Drug Class, 2016-2026 (US$ Mn)
4.1 Overview
4.2 Bisphosphonates
4.2.1 Clodronate
4.2.2 Etidronate
4.2.3 Ibandronate
4.2.4 Pamidronate
4.2.5 Zoledronic acid
4.3 Calcimimetic Agents
4.4 Calcitonin
4.5 Denusomab
4.6 Glucocorticoids
4.7 Pipeline Analysis
4.7.1 Phase III
4.7.1.1 KHK7580
4.7.2 Phase II & I (Tabular Information)

Chapter 5 Global Hypercalcemia Treatment Market, by Geography, 2016-2026 (US$ Mn)
5.1 Overview
5.2 North America Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
5.2.1 North America Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.2.2 North America Hypercalcemia Treatment Market, by Country, 2016–2026 (US$ Mn)
5.2.2.1 United States
5.2.2.2 Canada
5.3 Europe Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
5.3.1 Europe Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.3.2 Europe Hypercalcemia Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 Rest of Europe
5.4 Asia Pacific Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
5.4.1 Asia Pacific Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.4.2 Asia Pacific Hypercalcemia Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
5.4.2.1 Japan
5.4.2.2 China
5.4.2.3 Rest of Asia Pacific
5.5 Latin America Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
5.5.1 Latin America Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.5.2 Latin America Hypercalcemia Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
5.5.2.1 Brazil
5.5.2.2 Mexico
5.5.2.3 Rest of LATAM
5.6 Middle East & Africa Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
5.6.1 Middle East & Africa Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.6.2 Middle East & Africa Hypercalcemia Treatment Market, by Region, 2016–2026 (US$ Mn)
5.6.2.1 GCC
5.6.2.2 Rest of MEA

Chapter 6 Company Profiles
6.1 Amgen, Inc.
6.1.1 Business Description
6.1.2 Financial Information
6.1.3 Product Portfolio
6.1.4 Key Developments
6.2 Bayer Pharma AG
6.3 Cipla, Inc.
6.4 Dr. Reddy’s Laboratories, Ltd.
6.5 Mylan N.V.
6.6 Novartis AG
6.7 Pfizer, Inc.
6.8 Sun Pharmaceutical Industries, Ltd.

List of Figures
FIG. 1 Market Segmentation: Global Hypercalcemia Treatment Market
FIG. 2 Global Hypercalcemia Treatment Market: Research Methodology
FIG. 3 Global Hypercalcemia Treatment Market, by Drug Class, 2017 (US$ Mn)
FIG. 4 Global Hypercalcemia Treatment Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition, by Geography, 2017
FIG. 6 Competitive Analysis: Global Hypercalcemia Treatment Market, by Key Players, 2017
FIG. 7 Global Clodronate Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 8 Global Etidronate Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 9 Global Ibandronate Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 10 Global Pamidronate Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 11 Global Zoledronic acid Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 12 Global Calcimimetic Agents Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 13 Global Calcitonin Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 14 Global Denusomab Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 15 Global Glucocorticoids Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 16 Global KHK7580 Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
FIG. 17 U.S. Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 18 Canada Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 19 U.K. Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 20 Germany Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 21 Rest of Europe Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 22 Japan Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 23 China Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 24 Rest of Asia Pacific Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 25 Brazil Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 26 Mexico Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 27 Rest of Latin America Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 28 GCC Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)
FIG. 29 Rest of Middle East & Africa Hypercalcemia Treatment Market, 2016–2026 (US$ Mn)

List of Tables
TABLE 1 Global Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 2 Global Bisphosphonates Market for Hypercalcemia Treatment, 2016–2026 (US$ Mn)
TABLE 3 Global Hypercalcemia Treatment Market, by Geography, 2016–2026 (US$ Mn)
TABLE 4 Hypercalcemia Phase II & I Drugs Tabular Information
TABLE 5 North America Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 6 North America Hypercalcemia Treatment Market, by Country, 2016–2026 (US$ Mn)
TABLE 7 Europe Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 8 Europe Hypercalcemia Treatment Market, by Country, 2016–2026 (US$ Mn)
TABLE 9 Asia Pacific Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 10 Asia Pacific Hypercalcemia Treatment Market, by Country, 2016–2026 (US$ Mn)
TABLE 11 Latin America Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 12 Latin America Hypercalcemia Treatment Market, by Country, 2016–2026 (US$ Mn)
TABLE 13 Middle East & Africa Hypercalcemia Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 14 Middle East & Africa Hypercalcemia Treatment Market, by Region, 2016–2026 (US$ Mn)
TABLE 15 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Bayer Pharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Cipla, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Dr. Reddy’s Laboratories, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Sun Pharmaceutical Industries, Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amgen, Inc.
  • Bayer Pharma AG
  • Cipla, Inc.
  • Dr. Reddy’s Laboratories, Ltd.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries, Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll